Clinical Trials
Wednesday, December 18th, 2013
ASA: 11/14/13 Background and Purpose—Patients with acute ischemic stroke benefit from rapid evaluation and treatment, and timely brain imaging is a necessary component. We determined the effect of a targeted behavioral intervention on door-to-imaging time (DIT) among patients with ischemic stroke treated with tissue-type plasminogen activator. Second, we examined the variation in DIT accounted for by […]
Atrial Fibrillation
Saturday, December 14th, 2013
NEJM: 12/12/13 BACKGROUND The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy. METHODS We conducted a multicenter, randomized, controlled trial involving patients with […]
Atrial Fibrillation
Saturday, December 14th, 2013
CIRCULATIONAHA: December 9, 2013 Background—Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the RE-LY trial dabigatran, with approximately 80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150 mg dose, and significantly less major bleeding in the 110 mg dose in […]
Atrial Fibrillation
Saturday, December 14th, 2013
Neurology: December 6, 2013 Objective: To evaluate the safety and feasibility of percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) and previous intracranial hemorrhage (ICH). Methods: In an explorative, prospective, single-center, observational study, LAAO was performed in patients with previous ICH and AF using the Amplatzer Cardiac Plug device. Risks of ischemic strokes and […]
Clinical Trials
Saturday, December 14th, 2013
NIH: Thursday, December 12, 2013 Stroke remains number one cause of disability and fourth leading cause of death in the United States A network of 25 regional stroke centers working with nearby satellite facilities will span the country, have teams of researchers representing every medical specialty needed for stroke care and will address the three […]
Clinical Trials
Saturday, December 14th, 2013
BMC Medical Research Methodology: December 7, 2013 Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, […]
Clinical Trials
Saturday, December 14th, 2013
BMJ: 12/5/13 FDA investigator Thomas Marciniak has spoken out over drug companies and missing or “bad” data, most famously over rosiglitazone. He tells Deborah Cohenhow he believes the current research and development process is broken The clinical trial system is broken and it’s getting worse, according to longstanding Food and Drug Administration investigator, Thomas Marciniak. For seasoned […]
Clinical Trials
Saturday, December 14th, 2013
Wiley: DEC 1, 2013 Background Our randomized controlled trial of a multifaceted evidence-based intervention for improving the inpatient management of fever, hyperglycemia, and swallowing dysfunction in the first three-days following stroke improved outcomes at 90 days by 15%. We designed a quantitative process evaluation to further explain and illuminate this finding. Methods Blinded retrospective medical record […]
Clinical Trials
Saturday, December 14th, 2013
Biostatistics: September 25, 2013 The accuracy of published medical research is critical for scientists, physicians and patients who rely on these results. However, the fundamental belief in the medical literature was called into serious question by a paper suggesting that most published medical research is false. Here we adapt estimation methods from the genomics community to […]
Therapies
Saturday, December 14th, 2013
STROKEAHA: December 12, 2013 Background and Purpose—When optimally managed, patients with stroke are less likely to have further vascular events. We aimed to identify factors associated with optimal use of secondary prevention therapies in long-term survivors of stroke. Methods—We carefully documented discharge medications at baseline and self-reported use of medications at annual follow-up in the Northeast Melbourne […]
